USANA Health Sciences Financial Statements (USNA)
|
|
|
|
Report date
|
|
|
01.03.2022 |
28.02.2023 |
27.02.2024 |
12.03.2025 |
16.03.2026 |
|
12.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 186 |
998.6 |
921.0 |
854.5 |
925.3 |
|
925.9 |
|
Operating Income, bln rub |
|
|
170.2 |
107.6 |
93.1 |
66.3 |
50.9 |
|
49.1 |
|
EBITDA, bln rub |
? |
|
192.9 |
130.2 |
123.1 |
98.9 |
82.1 |
|
78.3 |
|
Net profit, bln rub |
? |
|
116.5 |
69.4 |
63.8 |
42.0 |
10.8 |
|
8.87 |
|
|
OCF, bln rub |
? |
|
121.2 |
103.9 |
70.6 |
61.0 |
22.3 |
|
16.6 |
|
CAPEX, bln rub |
? |
|
12.8 |
10.4 |
14.5 |
10.1 |
13.8 |
|
13.7 |
|
FCF, bln rub |
? |
|
108.5 |
93.5 |
56.1 |
50.9 |
8.53 |
|
2.96 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
|
|
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
785.3 |
683.7 |
638.5 |
612.4 |
673.5 |
|
661.3 |
|
Cost of production, bln rub |
|
|
230.9 |
207.3 |
189.4 |
175.8 |
200.9 |
|
215.6 |
|
R&D, bln rub |
|
|
11.1 |
11.6 |
11.4 |
11.6 |
0.000 |
|
0.000 |
|
Interest expenses, bln rub |
|
|
0.057 |
0.192 |
0.262 |
0.281 |
0.842 |
|
0.671 |
|
|
Assets, bln rub |
|
|
577.7 |
596.5 |
632.8 |
748.2 |
742.9 |
|
739.0 |
|
Net Assets, bln rub |
? |
|
395.1 |
434.5 |
497.2 |
532.1 |
533.1 |
|
543.6 |
|
Debt, bln rub |
|
|
17.3 |
13.8 |
13.2 |
39.2 |
14.0 |
|
14.0 |
|
Cash, bln rub |
|
|
239.8 |
288.4 |
330.4 |
181.8 |
158.4 |
|
162.8 |
|
Net debt, bln rub |
|
|
-222.5 |
-274.6 |
-317.2 |
-142.6 |
-144.4 |
|
-148.8 |
|
|
Ordinary share price, rub |
|
|
101.2 |
|
|
|
|
|
18.4 |
|
Number of ordinary shares, mln |
|
|
20.1 |
19.3 |
19.3 |
19.1 |
18.6 |
|
18.4 |
|
|
Market cap, bln rub |
|
|
2 039 |
0 |
0 |
0 |
0 |
|
338 |
|
EV, bln rub |
? |
|
1 816 |
-275 |
-317 |
-143 |
-144 |
|
189 |
|
Book value, bln rub |
|
|
347 |
385 |
450 |
236 |
262 |
|
277 |
|
|
EPS, rub |
? |
|
5.78 |
3.60 |
3.31 |
2.20 |
0.58 |
|
0.48 |
|
FCF/share, rub |
|
|
5.38 |
4.86 |
2.92 |
2.67 |
0.46 |
|
0.16 |
|
BV/share, rub |
|
|
17.2 |
20.0 |
23.4 |
12.4 |
14.1 |
|
15.0 |
|
|
EBITDA margin, % |
? |
|
16.3% |
13.0% |
13.4% |
11.6% |
8.87% |
|
8.46% |
|
Net margin, % |
? |
|
9.82% |
6.94% |
6.93% |
4.92% |
1.16% |
|
0.96% |
|
FCF yield, % |
? |
|
5.32% |
|
|
|
|
|
0.88% |
|
ROE, % |
? |
|
29.5% |
16.0% |
12.8% |
7.90% |
2.02% |
|
1.63% |
|
ROA, % |
? |
|
20.2% |
11.6% |
10.1% |
5.62% |
1.45% |
|
1.20% |
|
|
P/E |
? |
|
17.5 |
0.00 |
0.00 |
0.00 |
0.00 |
|
38.0 |
|
P/FCF |
|
|
18.8 |
0.00 |
0.00 |
0.00 |
0.00 |
|
114.0 |
|
P/S |
? |
|
1.72 |
0.00 |
0.00 |
0.00 |
0.00 |
|
0.36 |
|
P/BV |
? |
|
5.88 |
0.00 |
0.00 |
0.00 |
0.00 |
|
1.22 |
|
EV/EBITDA |
? |
|
9.42 |
-2.11 |
-2.58 |
-1.44 |
-1.76 |
|
2.41 |
|
Debt/EBITDA |
|
|
-1.15 |
-2.11 |
-2.58 |
-1.44 |
-1.76 |
|
-1.90 |
|
|
R&D/CAPEX, % |
|
|
87.1% |
111.2% |
79.0% |
114.9% |
0.00% |
|
0 |
|
|
CAPEX/Revenue, % |
|
|
1.08% |
1.04% |
1.57% |
1.18% |
1.49% |
|
1.48% |
|
| USANA Health Sciences shareholders |
